Active Immuno-Oncology Therapy
OBI-866 is an immunotherapeutic cancer vaccine targeting SSEA-4, a tumor-associated carbohydrate antigen highly expressed in many cancers. OBI-866 is a conjugate of SSEA-4 and a carrier protein, keyhole limpet hemocyanin (KLH). OBI-866 is designed to be used in combination with the adjuvant OBI-821, to elicit SSEA-4 specific IgM and IgG immune responses therapeutically.
The advantage of OBI-866 lies within the inherent property of a vaccine — activating patients’ own immune system to fight diseases, in this case fighting cancers. When patients’ immune system has the ability to exert cytotoxic killing effect on SSEA-4 expressing tumor cells, it provides long-term protection against the disease. Compared with conventional chemotherapy, immunotherapy reduces the damage to normal cells and further lowers the severity of toxicity-related side effects. As targeted tumor cells typically have higher SSEA-4 expression, the required anti-SSEA-4 antibody levels for effective anti-cancer therapy can be induced at low dose of OBI-866. OBI-866 thus can potentially be a safer and more effective treatment than standard chemotherapy and targeted therapy for cancer treatment.
OBI-866 is currently in a phase I dose escalation study.